Business
Neovia Oncology and Creatv Bio collaborate on NEV-801 liquid biopsy studies for solid tumors
Neovia Oncology, a Bellevue, Washington-based clinical-stage company, has entered a research collaboration with Monmouth Junction, New Jersey-based Creatv...
NewLimit raises USD 435m Series C to advance aging reprogramming medicine toward human trials
South San Francisco-based NewLimit, a biotechnology company focused on longevity medicine, has closed a USD 435 million Series C funding round as it...
UK immune profiling biotech IMU Bio closes Series A extension at over USD 53m
London-based IMU Biosciences has closed an oversubscribed extension to its Series A financing round, bringing the total raise to over USD 53 million (GBP 40...
Avenzo to gain Nasdaq listing via reverse merger with Rallybio, alongside USD 215m fund raise
Connecticut-based Rallybio Corporation (Nasdaq: RLYB) has agreed to acquire private San Diego-based Avenzo Therapeutics, Inc. in a reverse merger that will...
Eli Lilly expands Camurus FluidCrystal collaboration to amylin receptor agonists, USD 870m deal
Eli Lilly (NYSE: LLY) has expanded its collaboration with Camurus (Nasdaq Stockholm: CAMX) to include amylin receptor agonists, exercising a pre-negotiated...
SK Bio secures USD 230m in government financing for Sanofi-partnered pneumococcal vaccine
SK bioscience, the Songdo, Incheon-based vaccine and biotech company, has secured KRW 300 billion (approximately USD 230 million) in long-term, low-interest...
Servier acquires Edgewise muscular dystrophy business for USD 2.65b including sevasemten rights
France-based Servier will acquire sevasemten and Edgewise Therapeutics' muscular dystrophy business for USD 1.55 billion in upfront cash plus up to USD 1.1...
Oak Hill Bio raises USD 32.5m Series A to advance rugonersen toward pivotal Angelman trial
Cambridge, Massachusetts-based Oak Hill Bio, a clinical-stage rare disease company focused on repurposing deprioritized pharma assets, has closed a USD 32.5...
Curium commits EUR 32m strategic investment to Saclay radiopharmaceuticals facility
Curium, the Paris-headquartered radiopharmaceutical company, has announced a strategic capital investment exceeding EUR 32 million at its Saclay, France...
Lilly licenses Hanmi's GLP-2 agonist sonefpeglutide in USD 1.26b deal
Eli Lilly (NYSE: LLY) has agreed to pay USD 75 million upfront to license sonefpeglutide, a long-acting GLP-2 receptor agonist biologic, from South Korean...
Agios bags license to Oscotec's SYK inhibitor cevidoplenib in USD 165m deal
Agios Pharmaceuticals (Nasdaq: AGIO) has licensed exclusive global rights to cevidoplenib, a next-generation oral SYK inhibitor developed by South Korean...
Lilly strikes USD 3.05b multi-program licensing collaboration with China's Haisco Pharma
Eli Lilly (NYSE: LLY) has struck a multi-program licensing and research collaboration with Haisco Pharmaceutical Group (SZSE: 002653) worth up to USD 3.05...
Lunai Bioworks and BrainStorm Therapeutics launch foundation-funded Parkinson's and rare epilepsy AI collaboration
Lunai Bioworks and BrainStorm Therapeutics have launched a foundation-funded neurology collaboration pairing AI-driven target discovery with human brain...
CSPC receives AZ's USD 1.2b upfront from long-acting peptide collaboration
AstraZeneca has confirmed receipt of a USD 1.2 billion upfront payment by CSPC Pharmaceutical Group (HKEX: 1093) under a strategic collaboration and license...
Ratio Therapeutics expands PharmaLogic manufacturing collaboration for Ac-225RTX-2358 alpha therapy
Ratio Therapeutics has expanded its manufacturing collaboration with radiopharmaceutical CDMO PharmaLogic Holdings Corp. to scale clinical supply of...
The AllSci Brief
Systematic R&D and deal news. Daily.